Abstract:Background Congenital heart disease (CHD) represents a significant contributor to both morbidity and mortality in neonates and children. The prompt recognition of CHD can facilitate timely and appropriate intervention, reducing the probability of complications and enhancing the prognosis for impacted newborns. However, unlike other rare conditions routinely identified through federal and state newborn screening (NBS) programs, there’s currently no analogous dried blood spot (DBS) screening for CHD immediately after birth. Objective This study was set to identify reliable metabolite biomarkers with clinical relevance, with the aim to assess feasibility of screening and subtype classification of CHD utilizing the DBS newborn screening method. Methods We assembled a cohort of DBS datasets from the California Department of Public Health (CDPH) Biobank, encompassing both normal controls and three pre-defined CHD categories (tetralogy of Fallot, inherited arrhythmia syndrome, neonatal cardiomyopathy). A robust, DBS-oriented metabolomic method, employing both global and targeted strategies based on liquid chromatography with tandem mass spectrometry (LC-MS/MS), was developed. To verify the reliability of this metabolic profiling, we conducted a correlation analysis comparing the absolute quantitated metabolite concentration in DBS against the CDPH NBS records. Additionally, for hydrophilic and hydrophobic metabolites, we executed significant pathway and metabolite analyses respectively. Finally, logistic and LightGBM models were established to aid in CHD discrimination and classification. Results Our metabolomic workflow demonstrated consistent and reliable quantification of metabolites in DBS samples stored at the California Department of Public Health (CDPH) for up to 15 years. Through this process, we discerned dysregulated metabolic pathways in CHD patients, including deviations in lipid and energy metabolism, as well as oxidative stress pathways. Furthermore, we identified three metabolites as potential biomarkers for CHD assessment, and an additional twelve metabolites as potential markers for classifying different CHD subtypes within DBS samples. Conclusions This study represents the first attempt to validate metabolite profiling results using long-term storage DBS samples procured from the high-quality conditions of the CDPH biobank. The results unveil distinct metabolic discrepancies between various CHD subtypes and healthy controls. Furthermore, our findings highlight the potential clinical applications of our DBS-based methods for CHD screening and subtype classification. ### Competing Interest Statement K.J. Su, Q. Tang, J. Schilling, B. Jin are staff members of mProbe Inc. The rest of the authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. ### Funding Statement This study did not receive any funding. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee/IRB of Stanford University gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors <http://translationalmedicine.stanford.edu>

Biospecimens in the HEALthy Brain and Child Development (HBCD) Study: Rationale and protocol

Advancing high quality longitudinal data collection: Implications for the HEALthy Brain and Child Development (HBCD) Study design and recruitment

An introduction to the HEALthy Brain and Child Development Study (HBCD) study

Capturing the complexity of child behavior and caregiver-child interactions in the HEALthy Brain and Child Development (HBCD) Study using a rigorous and equitable approach

The HEALthy Brain and Child Development Study (HBCD) experience: Recruiting and retaining diverse families in a longitudinal, multi-method early childhood study

Infant and early childhood physical health assessments in the HEALthy Brain and Child Development (HBCD) Study

Measurement of emerging neurocognitive and language skills in the HEALthy Brain and Child Development (HBCD) study

Quantifying brain development in the HEALthy Brain and Child Development (HBCD) Study: The magnetic resonance imaging and spectroscopy protocol

Communications, engagement, and dissemination strategies for the HEALthy Brain and Child Development (HBCD) Study

Assessing prenatal and early childhood social and environmental determinants of health in the HEALthy Brain and Child Development Study (HBCD)

Navigating ethical and legal challenges in the HEALthy Brain and Child Development Study: Lessons learned from the ethics, law, policy working group

The development and structure of the HEALthy Brain and Child Development (HBCD) Study EEG protocol

The UNC/UMN Baby Connectome Project (BCP): an Overview of the Study Design and Protocol Development

Remote data collection of infant activity and sleep patterns via wearable sensors in the HEALthy Brain and Child Development Study (HBCD)

An open resource for transdiagnostic research in pediatric mental health and learning disorders

Assessment of a multisite standardized biospecimen collection protocol for immune phenotyping in neurodevelopmental disorders

A pilot study to understand feasibility and acceptability of stool and cord blood sample collection for a large-scale longitudinal birth cohort

Towards a more inclusive and equitable developmental cognitive neuroscience

A Metabolic Biomarker Panel for Congenital Heart Disease Assessment with Newborn Dried Blood Spots

Cohort profile: Understanding Pregnancy Signals and Infant Development (UPSIDE): a pregnancy cohort study on prenatal exposure mechanisms for child health

Protocol for a Longitudinal Twin Birth Cohort Study to Unravel the Complex Interplay Between Early-Life Environmental and Genetic Risk Factors in Health and Disease: the Chongqing Longitudinal Twin Study (Lotis)